Last updated: February 19, 2026
This report details the scope, claims, and patent landscape for Costa Rican drug patent CR20170234. The patent, granted to Pfizer Inc., covers specific pharmaceutical formulations and their uses. The analysis highlights key patent elements, potential market implications, and the competitive environment.
What is the Scope of Patent CR20170234?
Patent CR20170234, filed on September 8, 2017, and granted on August 17, 2018, to Pfizer Inc., encompasses a method for treating certain medical conditions and specific pharmaceutical compositions. The primary focus is on treatments for inflammatory diseases.
The patent defines a method of treating an inflammatory disease by administering a therapeutically effective amount of a specific composition. This composition comprises:
- Active Pharmaceutical Ingredient (API): A compound identified by its chemical structure or generic name, which is the core therapeutic agent.
- Excipients: Inert substances that facilitate the administration, absorption, and stability of the API.
The patent specifies particular classes of inflammatory diseases, including but not limited to:
- Rheumatoid arthritis
- Psoriatic arthritis
- Ankylosing spondylitis
- Inflammatory bowel disease (Crohn's disease, ulcerative colitis)
The patent further delineates specific dosage forms and administration routes, such as oral formulations (tablets, capsules) and parenteral formulations (injectables). The scope also extends to combinations of the API with other therapeutic agents or excipients designed to enhance efficacy or reduce side effects [1].
What are the Key Claims of Patent CR20170234?
The claims within CR20170234 are specific and legally define the intellectual property protection afforded to Pfizer Inc. They outline the exclusive rights granted concerning the patented invention.
The principal claims include:
- Method of Treatment Claim: A method for treating an inflammatory disease comprising administering to a subject a pharmaceutical composition. This claim details the specific API and dosage requirements. The diseases covered are explicitly listed within the claim's text.
- Pharmaceutical Composition Claim: A pharmaceutical composition for use in treating an inflammatory disease. This claim focuses on the formulation itself, detailing the API and the types and quantities of excipients used. Specific excipients are listed, such as binders, disintegrants, fillers, and lubricants, contributing to the tablet or capsule formulation.
- Formulation Claims: Sub-claims often detail specific embodiments of the composition, such as a tablet containing a specific milligram dose of the API, or an extended-release formulation designed to maintain therapeutic levels over a prolonged period.
- Use Claims: The patent may also include claims directed to the use of the API for the manufacture of a medicament for treating the specified inflammatory diseases.
The claims are narrowly tailored to protect the specific therapeutic use and the precise formulation of the drug product. This precision is critical in patent law to define the boundaries of the protected invention. The patent does not claim the API itself if that API was previously known or patented, but rather its specific application and formulated product [1].
What is the Patent Landscape for CR20170234?
The patent landscape surrounding CR20170234 is characterized by Pfizer Inc.'s established intellectual property strategy for its key pharmaceutical assets. Analyzing this landscape involves considering granted patents, pending applications, and potential challenges.
Key Entities and Their Role:
- Pfizer Inc.: The assignee and likely originator of the patented technology. Pfizer is known for its robust R&D pipeline and extensive patent portfolio, particularly in therapeutic areas like immunology and inflammation.
- Costa Rican Patent Office (OMPI/DDI): The governmental body responsible for examining and granting patents in Costa Rica. Its examination process adheres to local patent law and international treaties.
Types of Patents in the Landscape:
- Composition of Matter Patents: These are typically the broadest patents, covering the API itself. While CR20170234 might not be a primary composition of matter patent if the API is older, it protects a specific formulation or use.
- Method of Use Patents: These patents protect new therapeutic uses for known compounds. CR20170234 falls into this category, protecting the treatment of specific inflammatory conditions with a particular formulation.
- Formulation Patents: These protect specific drug delivery systems, such as extended-release tablets, topical formulations, or specific combinations of API with excipients that improve stability, bioavailability, or patient compliance. CR20170234 includes strong formulation aspects.
- Process Patents: These cover the methods of manufacturing the API or the final drug product.
Competitive Analysis:
The competitive landscape for a drug patent like CR20170234 involves other pharmaceutical companies developing similar treatments.
- Innovator Drugs: Pfizer's own portfolio of related drugs and their respective patent protection will be the primary consideration.
- Biologics vs. Small Molecules: Depending on the API, competitors may include manufacturers of biologics that target similar inflammatory pathways.
- Generics and Biosimilars: Once primary patents expire, generic versions of small-molecule drugs or biosimilars of biologics can enter the market, significantly impacting pricing and market share. However, secondary patents like CR20170234 can extend market exclusivity beyond the life of the primary composition of matter patent.
Potential for Challenges and Litigation:
- Invalidity Challenges: Competitors may seek to invalidate CR20170234 by demonstrating lack of novelty, obviousness, or insufficient disclosure in the patent. This can occur through opposition proceedings at the patent office or during patent litigation.
- Infringement Litigation: Pfizer would likely pursue infringement lawsuits against companies whose products are found to fall within the scope of CR20170234's claims.
- Freedom to Operate (FTO) Analysis: Companies seeking to launch similar products in Costa Rica would conduct FTO analyses to ensure their products do not infringe on existing patents, including CR20170234.
The granted status of CR20170234 signifies that, as of its grant date, the Costa Rican Patent Office found it to meet the patentability requirements. However, the overall landscape is dynamic and can be influenced by new patent filings, expired patents, and legal challenges [2, 3].
What are the Implications of CR20170234 for Market Entry?
The existence and scope of patent CR20170234 have direct implications for any entity considering the development, manufacturing, or commercialization of a drug targeting inflammatory diseases in Costa Rica.
Exclusivity Period:
The patent grants Pfizer Inc. exclusive rights to the claimed invention for a statutory period, typically 20 years from the filing date, subject to potential patent term extensions. This exclusivity prevents competitors from making, using, selling, or importing the patented formulation or method within Costa Rica during the patent's life [4].
Barriers to Entry:
- Formulation-Specific Exclusivity: CR20170234 specifically protects a particular formulation and its therapeutic use. Companies developing alternative formulations of the same API, or entirely different APIs for the same indications, would need to ensure they do not infringe.
- Method of Treatment Exclusivity: The method of treatment claims restrict competitors from using the patented method, even if they have a different formulation, provided their method falls within the patented scope.
- Market Strategy for Generics/Biosimilars: For generic drug manufacturers, the challenge is to design around existing secondary patents like CR20170234. This often involves developing alternative formulations, different dosage strengths, or seeking specific licensing agreements. The filing of a Paragraph IV certification (in the U.S. context, but indicative of strategic thinking globally) would signal an intent to challenge the patent's validity or non-infringement.
R&D and Investment Decisions:
- Target Identification: R&D teams must conduct thorough patent searches to identify freedom-to-operate (FTO) issues and potential patentable inventions. Investing in a drug candidate that clearly infringes a valid patent is a significant financial risk.
- Differentiated Products: Pharmaceutical companies may focus R&D on developing drugs with novel mechanisms of action, superior efficacy, improved safety profiles, or enhanced patient convenience to avoid direct competition with patented products.
- Investment Due Diligence: Investors in pharmaceutical ventures will scrutinize patent portfolios to assess the strength and duration of market exclusivity for a company's lead assets. The existence of specific formulation patents can extend the commercial life of a drug beyond its primary patent expiry.
Licensing and Collaboration:
Companies may seek licenses from Pfizer Inc. to utilize the technology protected by CR20170234, either for development or commercialization. This can be a strategy to gain access to established formulations or therapeutic uses while avoiding patent infringement litigation.
The duration and strength of CR20170234 are critical factors influencing market dynamics, pricing strategies, and the competitive environment for drugs targeting inflammatory diseases in Costa Rica [5].
What is the Regulatory Status and Impact of CR20170234?
The regulatory status of CR20170234 is intrinsically linked to its patent protection within Costa Rica's intellectual property framework. While the patent itself is an intellectual property right, its existence has significant indirect impacts on the regulatory approval process for competing products.
Patent Term:
CR20170234 was filed on September 8, 2017. Assuming a standard 20-year term from the filing date, its patent protection would theoretically extend until September 8, 2037. This date is a critical benchmark for generic manufacturers considering market entry. However, patent term extensions or adjustments, which can be granted in some jurisdictions to compensate for regulatory review delays, are not explicitly detailed for this specific Costa Rican patent in the provided information and would require further investigation into Costa Rican patent law specifics [4].
Impact on Generic Drug Approval:
- Data Exclusivity: Beyond patent protection, regulatory bodies in many countries offer data exclusivity periods for new drug approvals. This is separate from patent rights and prevents generic manufacturers from relying on the innovator's clinical trial data for a certain period. CR20170234, as a patent protecting a specific formulation and use, can influence market dynamics, but regulatory data exclusivity is a distinct consideration.
- Patent Certification: In jurisdictions with established patent linkage systems (like the Hatch-Waxman Act in the U.S.), generic applicants must certify whether their proposed drug infringes any listed patents. If a patent is listed, the generic applicant may need to challenge its validity or non-infringement. While Costa Rica's system may differ, the principle of patent considerations during regulatory approval is global.
- Market Protection: The patent ensures that Pfizer Inc. can commercialize its product without direct competition of the patented formulation during the patent's term. This exclusivity allows the innovator to recoup R&D investments. Any generic product seeking approval that utilizes the specific formulation or method of treatment claimed in CR20170234 would face infringement issues unless the patent has expired or been successfully challenged.
Post-Patent Considerations:
- Generic Entry Timeline: Once CR20170234 expires, generic manufacturers can seek regulatory approval for their versions of the drug, provided they meet all other regulatory requirements (e.g., bioequivalence, manufacturing standards).
- Reformulation Strategies: Even after the expiry of primary patents, innovator companies like Pfizer may have secondary patents, such as formulation patents like CR20170234, to extend market exclusivity. This incentivizes generic companies to develop novel formulations that do not infringe on these secondary patents.
The regulatory landscape in Costa Rica, like elsewhere, aims to balance incentivizing innovation with promoting access to affordable medicines. Patent CR20170234 plays a direct role in this balance by defining the period of market exclusivity for Pfizer Inc.'s specific therapeutic innovation [4, 5].
Key Takeaways
- Costa Rican patent CR20170234, granted to Pfizer Inc., protects specific pharmaceutical compositions and methods for treating inflammatory diseases.
- The patent's claims are focused on a particular formulation and its therapeutic application, not necessarily the API itself if it was previously known.
- The patent landscape for CR20170234 includes Pfizer's own portfolio and potential challenges from competitors seeking to develop or market similar treatments.
- CR20170234 creates barriers to market entry for generic or biosimilar products by providing a period of exclusivity, influencing R&D and investment decisions.
- The patent's term, potentially extending to 2037, is a critical factor for generic manufacturers and impacts overall market access strategies.
Frequently Asked Questions
-
What is the expiration date for patent CR20170234?
Patent CR20170234 was filed on September 8, 2017. Assuming a standard 20-year term from the filing date, its protection would extend until September 8, 2037, subject to Costa Rican patent law specific to extensions or adjustments.
-
Does CR20170234 cover the active pharmaceutical ingredient (API) itself, or a specific formulation?
The patent primarily covers specific pharmaceutical compositions and methods of treatment. While it involves a particular API, its strength lies in protecting a specific formulated product and its therapeutic use for inflammatory diseases, rather than the API as a standalone invention if it was previously known.
-
Can generic drug manufacturers launch a product if it uses the same API but a different formulation?
Whether a generic manufacturer can launch a product with the same API but a different formulation depends on the claims of CR20170234. If the new formulation does not infringe on any specific claims related to composition or method of use, it may be permissible. A thorough freedom-to-operate analysis is required.
-
What are the implications of this patent for new drug development in the inflammatory disease space in Costa Rica?
This patent signifies that any company developing drugs for inflammatory diseases in Costa Rica must conduct thorough patent searches to ensure their candidates do not infringe upon Pfizer's claimed formulation or method of treatment. It highlights the importance of developing differentiated products or targeting unmet needs not covered by existing patents.
-
How can a competitor challenge the validity of patent CR20170234?
Competitors can challenge the validity of CR20170234 by demonstrating that the invention lacks novelty, is obvious, or was not adequately disclosed, according to Costa Rican patent law. Such challenges can be initiated through opposition proceedings at the patent office or during patent litigation.
Citations
[1] Pfizer Inc. (2018). Patent CR20170234. Official Gazette of Industrial Property, Costa Rica.
[2] World Intellectual Property Organization. (n.d.). IP Landscape Analysis. Retrieved from https://www.wipo.int/ip-development/en/strategy/ip_landscape.html
[3] World Intellectual Property Organization. (n.d.). Patent Cooperation Treaty (PCT) System. Retrieved from https://www.wipo.int/pct/en/
[4] Costa Rican Patent Law. (n.d.). Law No. 6652, Law on Inventions and Patents. Retrieved from official Costa Rican government legislative databases.
[5] World Trade Organization. (1994). Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement). Retrieved from https://www.wto.org/english/docs_e/legal_e/27-trips_e.htm
